Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain scan could spot tumors more accurately than MRI

NCT ID NCT07698457

Diagnosis Sponsor: Primo Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial investigates whether a special PET scan using a radioactive tracer called 18F-FET can detect brain tumors (gliomas) more accurately than standard MRI. The study includes 30 patients with suspected gliomas and 6 healthy volunteers. The goal is to see if this imaging method improves diagnosis before surgery, with results compared to tissue analysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-Fluoroethyl-l-tyrosine (FET) – a radioactive tracer used in PET scans
What this could lead to
If successful, this imaging method could provide a more accurate way to detect and assess brain tumors before surgery, potentially improving treatment planning.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The tracer involves radiation exposure, though within safe limits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion criteria： For health volunteers 1. Participants must be ≥ 20 years old. 2. Participants are alert and oriented, and able to independently sign ICF. For glioma patients <!-- --> 1. Participants must be ≥ 20 years old. 2. Participants with suspected primary gliomas scheduled for surgery. 3. Participants are alert and oriented, and able to independently sign ICF. * Exclusion criteria： 1. Liver dysfunction within the past 6 months (e.g., AST/ALT ratio \> 2, total bilirubin \> 1.5 mg/dL). 2. Chronic kidney disease stage 4 (eGFR \< 30 mL/min/1.73 m2) within the last 6 months. 3. Acute kidney injury within the past 6 months. 4. Allergic to any radiopharmaceuticals or contrast agents. 5. Restlessness or inability to lie in a cast for 30 to 60 minutes. 6. Women who are pregnant, lactating, or planning pregnancy during the study period or before screening. 7. PI deemed the participant unsuitable. 8. The patient is not able to understand the treatment options.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 18F-fluoroethyl-L-tyrosine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

18F-fluoroethyl-L-tyrosine GLIOMA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chiayi Chang Gung Memorial Hospital

    Chiayi City, Puzi City, 613016, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 833401, Taiwan

  • Keelung Chang Gung Memorial Hospital

    Keelung, Maijin Rd., Anle Dist., 204, Taiwan

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City, Fuxing St., Guishan Dist., 333423, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.